

# Influenza Vaccination Recommendations

## Updates for 2016-2017

### What Providers Need to Know for the Influenza Season

The Advisory Committee on Immunization Practices (ACIP) has voted that Live Attenuated Influenza Vaccine (LAIV), also known as the "nasal spray" flu vaccine, should not be used during the 2016-2017 flu season. ACIP continues to recommend annual flu vaccination for everyone aged 6 months and older.

### Key Facts

- Based on CDC data, LAIV did not demonstrate enough evidence of effectiveness to warrant a recommendation. The reason for decreased effectiveness with LAIV is currently unknown.
- Preliminary estimates of vaccine effectiveness for LAIV among children 2 through 17 years during the 2015-2016 season was 3%, compared to Inactivated Influenza Vaccine (IIV) at 63%.<sup>1</sup>
- The change in the ACIP recommendation is an example of scientific research influencing policies to improve overall population health.

### Provider Information

- The Influenza Vaccine Information Statement (VIS) is not changing from the 2015-2016 season. To access go to [www.michigan.gov/immunize](http://www.michigan.gov/immunize) => Health Care Professionals/Providers => VIS at the top
- LAIV will not be available under the Vaccines for Children program.
- LAIV will be available through private supply, but in limited amounts. Using LAIV during the 2016-2017 flu season is off ACIP recommendations.
- All educational materials will still cover LAIV, but will include this statement "Live attenuated influenza vaccine (FluMist) is not recommended by CDC's Advisory Committee on Immunization Practices (ACIP) for use during the 2016-17 Influenza season in the United States."
- **Providers who make the decision to use LAIV at their practices will not have support or recommendations from MDHHS or the CDC, and must assume responsibility for any adverse events as a result of using LAIV.**